To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. If you experience any issues with your products or services, please contact ATCC Customer Service at sales@atcc.org. For Technical questions please contact tech@atcc.org. Thank you.
X

Privacy Policy Update

We remain dedicated to protecting your data and experience throughout our platforms. We have updated our Privacy Policy and your continued use of the Site means you have accepted the revised Privacy Policy. View now >
X
Search

Primary Renal Proximal Tubule Epithelial Cells; Normal, Human (RPTEC) (ATCC® PCS-400-010™)

Organism: Homo sapiens, human  /  Tissue: Kidney  /  Cell Type: Epithelial

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue Kidney
Cell Type Epithelial
Morphology Cuboidal with a characteristic pattern of swirled cells; refractile
Growth Properties Adherent
Biosafety Level 1

[These primary cells are not known to harbor an agent recognized to cause disease in healthy adult humans. Handle as a potentially biohazardous material under at least Biosafety Level 1 containment. Cells derived from primate lymphoid tissue may fall under the regulations of 29 CFR 1910.1030 Bloodborne Pathogens.  

ATCC recommends that appropriate safety procedures be used when handling all primary cells and cell lines, especially those derived from human or other primate material. Detailed discussions of laboratory safety procedures are provided in Laboratory Safety: Principles and Practice, 2nd ed. (ASM Press, Washington, DC) (Fleming et al., 1995) and Caputo, J.L. Biosafety procedures in cell culture. (1988) J. Tissue Culture Methods 11:223.

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS Publication No. (CDC) 93-8395. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online at http://www.cdc.gov/biosafety/publications/bmbl5/index.htm.]

Human Material Precaution 

All tissues used for isolation are obtained under informed consent and conform to HIPAA standards to protect the privacy of the donor’s personal health information. It is best to use caution when handling any human cells. We recommend that all human cells be accorded the same level of biosafety consideration as cells known to carry HIV. With infectious virus assays or viral antigen assays, even a negative test result may leave open the possible existence of a latent viral genome.


Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease Normal
Age Batch-specific
Gender Batch-specific
Ethnicity Batch-specific
Applications
Applications for use might include research related to hypertension; diabetes; oncology; renal fibrosis; inflammation; autoimmune disease; drug screening/development; and toxicology.
Product Format frozen 1 mL
Storage Conditions -130°C or below
Comments
A complete solution to propagate renal proximal tubule epithelial cells with excellent morphology in low serum (0.5% FBS) conditions.
Characterization: Pan-Cytokeratin (+), y-glutamyltransferase-1 (GGT-1) (+), TE-7 (-)
Complete Growth Medium
  1. Obtain one Renal Epithelial Cell Growth Kit from the freezer; make sure that the caps of all components are tight.
  2. Thaw the components of the growth kit just prior to adding them to the basal medium.
  3. Obtain one bottle of Renal Epithelial Cell Basal Medium (485 mL) from cold storage.
  4. Decontaminate the external surfaces of all growth kit component vials and the basal medium bottle by spraying them with 70% ethanol.
  5. Using aseptic technique and working in a laminar flow hood or biosafety cabinet, transfer the indicated volume of each growth kit component, as indicated in Table 1, to the bottle of basal medium using a separate sterile pipette for each transfer.
  6. Tightly cap the bottle of complete growth medium and swirl the contents gently to assure a homogeneous solution. Do not shake forcefully to avoid foaming. Label and date the bottle.
  7. Complete growth media should be stored in the dark at 2°C to 8°C (do not freeze). When stored under these conditions, complete growth media is stable for 30 days.

       Table 1. Renal Epithelial Cell Growth Kit Components 

Component

 

Volume

 

Final Concentration

 

Fetal Bovine Serum (FBS)

 

2.5 mL

 

0.5%

 

Triiodothyronine

 

0.5 mL

 

10 nM

 

rh EGF

 

1.0 mL

 

10 ng/mL

 

Hydrocortisone Hemisuccinate

 

0.5 mL

 

100 ng/mL

 

rh Insulin

 

0.5 mL

 

5 µg/ml

 

Epinephrine

 

0.5 mL

 

1.0 µM

 

Transferrin

 

0.5 mL

 

5 µg/ml

 

L-Alanyl-L-Glutamine

 

6.0 mL

 

2.4 mM

 

 

Antimicrobials and phenol red are not required for proliferation but may be added if desired. The recommended volume of either of the optional components to be added to the complete growth media is summarized in Table 2.

Table 2. Addition of Antimicrobials/Antimycotics and Phenol Red (Optional)

Component

Volume

Final Concentration

Penicillin-Streptomycin-Amphotericin B Solution

0.5 mL

Penicillin: 10 Units/mL

Streptomycin: 10 µg/mL

Amphotericin B: 25 µg/mL

Phenol Red

0.5 mL

33 µM
Subculturing
  1. Passage normal renal proximal tubule cells when the culture has reached approximately 95% confluence.
  2. Warm both the Trypsin-EDTA for Primary Cells (ATCC® PCS-999-003) and the Trypsin Neutralizing Solution (ATCC PCS-999-004) to room temperature prior to dissociation. Warm the complete growth medium to 37°C prior to use with the cells.
  3. For each flask, carefully aspirate the spent media without disturbing the monolayer.
  4. Rinse the cell layer one time with 3 to 5 mL D-PBS (ATCC 30-2200) to remove residual medium.
  5. Add pre-warmed trypsin-EDTA solution (1 to 2 mL for every 25 cm2) to each flask.
  6. Gently rock each flask to ensure complete coverage of the trypsin-EDTA solution over the cells, and then aspirate the excess fluid off of the monolayer.
  7. Observe the cells under the microscope. When the cells pull away from each other and round up (typically within 1 to 3 minutes), remove the flask from the microscope and gently tap it from several sides to promote detachment of the cells from the flask surface.
  8. When the majority of cells appear to have detached, quickly add an equal volume of the Trypsin Neutralizing Solution (ATCC PCS-999-004) to each flask. Gently pipette or swirl the culture to ensure all of the trypsin-EDTA solution has been neutralized.
  9. Transfer the dissociated cells to a sterile centrifuge tube and set aside while processing any remaining cells in the culture flask.
  10. Add 3 to 5 mL D-PBS (ATCC 30-2200) to the tissue culture flask to collect any additional cells that might have been left behind.
  11. Transfer the cell/D-PBS suspension to the centrifuge tube containing the trypsin-EDTA-dissociated cells.
  12. Repeat steps 10 and 11 as needed until all cells have been collected from the flask.
    Centrifuge the cells at 150 x g for 3 to 5 minutes.
  13. Aspirate neutralized dissociation solution from the cell pellet and resuspend the cells in 2 to 8 mL fresh, pre-warmed, complete growth medium.
  14. Count the cells and seed new culture flasks at a density of 5,000 viable cells per cm2.
  15. Place newly seeded flasks in a 37°C, 5% CO2 incubator for at least 24 to 48 hours before processing the cells further. Refer to Maintenance for guidelines on feeding.
Volume 1 mL
Cells per Vial One vial contains a minimum of 5 x 105  viable cells.
Sterility Tests
Bacteria and Yeast: Negative
Mycoplasma: Negative
Viral Testing
Hepatitis B: Negative
Hepatitis C: Negative
HIV: Negative
Viability ≥70% when thawed from cryopreservation
Population Doubling Capacity ≥ 15 in complete growth medium
C of A
Certificate of Analysis
Certificate of Analysis
Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
SDS
SDS
Other Documentation
Other Document
TransfeX Protocol - Primary RPTEC
References

Timpano S, Uniacke J. Human Cells Cultured under Physiological Oxygen utilize Two Cap-binding Proteins to Recruit Distinct mRNAs for Translation. J Biol Chem 291(20):10772-82, 2016. PubMed: 27002144

Ismail I, Mahmod Ilya I. Naphroprotective effect of Clinacanthus Nutans Against Cisplatin-Induced Human Kidney Cell (PCS-400-010). PMIO 4(S 01): S1-S202, 2017.

Edwards TG, Fisher C. Antiviral activity of pyrrole-imidazole polyamides against SV40 and BK polyomaviruses. Antiviral Res 152:68-75, 2018. PubMed: 29458134

Kaminska K, et al. Effects of cell-cell crosstalk on gene expression patterns in a cell model of renal cell carcinoma lung metastasis. Int J Oncol 52(3):768-786, 2018. PubMed: 29286165

Riwanto M, et al. Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycycstic Kidney Disease. PLoS One 11(1):e0146654, 2016. PubMed: 26752072

Freytag SO, et al. Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer. Mol Ther Oncolytics 2. Pii: 15006, 2015. PubMed: 26767191

Cioni M, et al. Comparing effects of DK virus agnoprotein and herpes simplex-1 ICP47 on MHC-I and MHC-II expression. Clin Dev Immunol 2013:626823, 2013. PubMed: 23606871

Weber HM, et al. Heparin-based hydrogels induce human renal tubulogenesis in vitro. Acta Biomater 57:59-69, 2017. PubMed: 28526628

Bethge T, et al. Imperfect Symmetry of Sp1 and Core Promoter Sequences Regulates Early and Late Virus Gene Expression of the Bidirectional BK Polyvirus Noncoding Control Region. J Virol 90(22):10083-10101, 2016. PubMed: 27581987

Habib A, et al. LISPRO mitigates b-amyloid and associated pathologies in Alzheimer’s mice. Cell Death Dis 8(6):e2880, 2017. PubMed: 28617434